⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155348 | 0.87 | — | — | |
| SCHEMBL1440930 | 0.81 | — | — | |
| SCHEMBL155312 | 0.79 | — | — | |
| SCHEMBL155496 | 0.77 | — | — | |
| SCHEMBL151703 | 0.75 | — | — | |
| SCHEMBL25418462 | 0.73 | — | — | |
| SCHEMBL155699 | 0.69 | — | — | |
| SCHEMBL154813 | 0.69 | — | — | |
| SCHEMBL155741 | 0.65 | GRIN2D (0.44) | — | |
| SCHEMBL6235140 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393907-A1 | POTASSIUM CHANNEL MODULATOR, COMPOSITION AND APPLICATION | Neushen Therapeutics (Shanghai) Co., Ltd (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-12018024-B2 | Compounds and compositions for the treatment of cryptosporidiosis | NOVARTIS AG (CH) | 2024-06-25 | — | — | US | disclosed |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | disclosed |
| EP-4229055-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | Novartis AG (CH) | 2023-08-23 | — | — | EP | disclosed |
| EP-4227304-A2 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| EP-3564233-B1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-3736271-B1 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-4105208-A1 | 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| EP-4101849-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| US-20100048620-A1 | COMPOSITION FOR TREATMENT OF UNDIFFERENTIATED GASTRIC CANCER | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048503-A1 | COMPOSITION FOR TREATMENT OF PANCREATIC CANCER | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090247576-A1 | ANTI-TUMOR AGENT FOR MULTIPLE MYELOMA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090209580-A1 | ANTITUMOR AGENT FOR THYROID CANCER | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090203693-A1 | THERAPEUTIC AGENT FOR LIVER FIBROSIS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |